Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277123 | 0.84 | TYRO3 (0.39) | BRD4 | |
| SCHEMBL16374566 | 0.81 | ROCK2 (0.40) | BRD4ROCK2MTORHTR6 | |
| SCHEMBL8169943 | 0.81 | ROCK2 (0.40) | BRD4ROCK2MTORHTR6 | |
| SCHEMBL7940303 | 0.74 | ROCK2 (0.35) | BRD4ROCK2MTORHTR6 | |
| SCHEMBL16374480 | 0.73 | KDM4E (0.40) | BRD4ROCK2HTR6 | |
| SCHEMBL3348822 | 0.73 | HTR6 (0.40) | BRD4HTR6 | |
| SCHEMBL16374478 | 0.72 | BRD4 (0.39) | BRD4ROCK2HTR6 | |
| SCHEMBL2752372 | 0.72 | PIK3CA (0.38) | BRD4ROCK2HTR6 | |
| SCHEMBL16374610 | 0.71 | KDM4E (0.39) | BRD4ROCK2HTR6 | |
| SCHEMBL2752527 | 0.71 | HTR6 (0.41) | BRD4ROCK2HIPK2CLK4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010015803-A1 | DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R & D MANAGEMENT CO. LTD (JP) | 2010-02-11 | — | — | WO | disclosed |